NPS Pharmaceuticals, Inc. (NPSP) Reports Characteristics of Patients Who Achieved Independence from Parenteral Support in STEPS 2 Study of Gattex® (teduglutide) in Adult Short Bowel Syndrome  
10/22/2012 9:34:27 AM

BEDMINSTER, N.J.--(BUSINESS WIRE)--NPS Pharmaceuticals, Inc. (NASDAQ: NPSP), a biopharmaceutical company developing innovative therapeutics for rare gastrointestinal and endocrine disorders, today reported data related to the seven patients who achieved complete independence from parenteral nutrition (PN) and/or intravenous fluids (IV) while on long-term Gattex® (teduglutide) therapy in STEPS 2, a 24-month, open-label study in adult short bowel syndrome (SBS).